Oral Antidiabetic (OAD) Treatment Market Report

Global Oral Antidiabetic (OAD) Treatment Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 08, 2022
  • PAGES：166
  • REPORT CODE：GMM861515
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Oral Antidiabetic (OAD) Treatment market report explains the definition, types, applications, major countries, and major players of the Oral Antidiabetic (OAD) Treatment market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Mannkind

    • Merck

    • Eli Lilly

    • Sanofi

    • Glenmark

    • Boehringer Ingelheim

    • Novartis

    • Pfizer

    • AstraZeneca

    • Novo Nordisk

    By Type:

    • Sulphonylureas

    • Biguanides

    • Intestinal α-Glucosidase Inhibitors

    • Others

    By End-User:

    • Hospital

    • Clinics

    • Diabetics Treatment Centres

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Oral Antidiabetic (OAD) Treatment Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Oral Antidiabetic (OAD) Treatment Outlook to 2028- Original Forecasts

    • 2.2 Oral Antidiabetic (OAD) Treatment Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Oral Antidiabetic (OAD) Treatment Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Oral Antidiabetic (OAD) Treatment Market- Recent Developments

    • 6.1 Oral Antidiabetic (OAD) Treatment Market News and Developments

    • 6.2 Oral Antidiabetic (OAD) Treatment Market Deals Landscape

    7 Oral Antidiabetic (OAD) Treatment Raw Materials and Cost Structure Analysis

    • 7.1 Oral Antidiabetic (OAD) Treatment Key Raw Materials

    • 7.2 Oral Antidiabetic (OAD) Treatment Price Trend of Key Raw Materials

    • 7.3 Oral Antidiabetic (OAD) Treatment Key Suppliers of Raw Materials

    • 7.4 Oral Antidiabetic (OAD) Treatment Market Concentration Rate of Raw Materials

    • 7.5 Oral Antidiabetic (OAD) Treatment Cost Structure Analysis

      • 7.5.1 Oral Antidiabetic (OAD) Treatment Raw Materials Analysis

      • 7.5.2 Oral Antidiabetic (OAD) Treatment Labor Cost Analysis

      • 7.5.3 Oral Antidiabetic (OAD) Treatment Manufacturing Expenses Analysis

    8 Global Oral Antidiabetic (OAD) Treatment Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Oral Antidiabetic (OAD) Treatment Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Oral Antidiabetic (OAD) Treatment Export by Region (Top 10 Countries) (2017-2028)

    9 Global Oral Antidiabetic (OAD) Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Sulphonylureas Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Biguanides Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Intestinal α-Glucosidase Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Diabetics Treatment Centres Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Oral Antidiabetic (OAD) Treatment Market Analysis and Outlook till 2022

    • 10.1 Global Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.2.2 Canada Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.2.3 Mexico Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.3.2 UK Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.3.3 Spain Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.3.4 Belgium Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.3.5 France Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.3.6 Italy Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.3.7 Denmark Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.3.8 Finland Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.3.9 Norway Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.3.10 Sweden Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.3.11 Poland Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.3.12 Russia Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.3.13 Turkey Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.4.2 Japan Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.4.3 India Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.4.4 South Korea Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.4.5 Pakistan Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.4.6 Bangladesh Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.4.7 Indonesia Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.4.8 Thailand Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.4.9 Singapore Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.4.10 Malaysia Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.4.11 Philippines Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.4.12 Vietnam Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.5.2 Colombia Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.5.3 Chile Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.5.4 Argentina Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.5.5 Venezuela Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.5.6 Peru Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.5.7 Puerto Rico Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.5.8 Ecuador Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.6.2 Kuwait Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.6.3 Oman Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.6.4 Qatar Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.7.2 South Africa Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.7.3 Egypt Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.7.4 Algeria Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

      • 10.8.2 New Zealand Oral Antidiabetic (OAD) Treatment Consumption (2017-2022)

    11 Global Oral Antidiabetic (OAD) Treatment Competitive Analysis

    • 11.1 Mannkind

      • 11.1.1 Mannkind Company Details

      • 11.1.2 Mannkind Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Mannkind Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

      • 11.1.4 Mannkind Oral Antidiabetic (OAD) Treatment Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Merck

      • 11.2.1 Merck Company Details

      • 11.2.2 Merck Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Merck Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

      • 11.2.4 Merck Oral Antidiabetic (OAD) Treatment Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Eli Lilly

      • 11.3.1 Eli Lilly Company Details

      • 11.3.2 Eli Lilly Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Eli Lilly Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

      • 11.3.4 Eli Lilly Oral Antidiabetic (OAD) Treatment Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Sanofi

      • 11.4.1 Sanofi Company Details

      • 11.4.2 Sanofi Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Sanofi Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

      • 11.4.4 Sanofi Oral Antidiabetic (OAD) Treatment Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Glenmark

      • 11.5.1 Glenmark Company Details

      • 11.5.2 Glenmark Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Glenmark Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

      • 11.5.4 Glenmark Oral Antidiabetic (OAD) Treatment Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Boehringer Ingelheim

      • 11.6.1 Boehringer Ingelheim Company Details

      • 11.6.2 Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

      • 11.6.4 Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Novartis

      • 11.7.1 Novartis Company Details

      • 11.7.2 Novartis Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Novartis Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

      • 11.7.4 Novartis Oral Antidiabetic (OAD) Treatment Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Pfizer

      • 11.8.1 Pfizer Company Details

      • 11.8.2 Pfizer Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Pfizer Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

      • 11.8.4 Pfizer Oral Antidiabetic (OAD) Treatment Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 AstraZeneca

      • 11.9.1 AstraZeneca Company Details

      • 11.9.2 AstraZeneca Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 AstraZeneca Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

      • 11.9.4 AstraZeneca Oral Antidiabetic (OAD) Treatment Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Novo Nordisk

      • 11.10.1 Novo Nordisk Company Details

      • 11.10.2 Novo Nordisk Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Novo Nordisk Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

      • 11.10.4 Novo Nordisk Oral Antidiabetic (OAD) Treatment Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    12 Global Oral Antidiabetic (OAD) Treatment Market Outlook by Types and Applications to 2028

    • 12.1 Global Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Sulphonylureas Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Biguanides Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Intestinal α-Glucosidase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Diabetics Treatment Centres Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.4 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Oral Antidiabetic (OAD) Treatment Market Analysis and Outlook to 2028

    • 13.1 Global Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.2.2 Canada Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.3.2 UK Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.3.3 Spain Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.3.5 France Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.3.6 Italy Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.3.8 Finland Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.3.9 Norway Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.3.11 Poland Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.3.12 Russia Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.4.2 Japan Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.4.3 India Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.5.3 Chile Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.5.6 Peru Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.6.3 Oman Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Oral Antidiabetic (OAD) Treatment Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Oral Antidiabetic (OAD) Treatment

    • Figure of Oral Antidiabetic (OAD) Treatment Picture

    • Table Global Oral Antidiabetic (OAD) Treatment Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Oral Antidiabetic (OAD) Treatment Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Sulphonylureas Consumption and Growth Rate (2017-2022)

    • Figure Global Biguanides Consumption and Growth Rate (2017-2022)

    • Figure Global Intestinal α-Glucosidase Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Diabetics Treatment Centres Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Oral Antidiabetic (OAD) Treatment Consumption by Country (2017-2022)

    • Table North America Oral Antidiabetic (OAD) Treatment Consumption by Country (2017-2022)

    • Figure United States Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Canada Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Mexico Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Oral Antidiabetic (OAD) Treatment Consumption by Country (2017-2022)

    • Figure Germany Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure UK Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Spain Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Belgium Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure France Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Italy Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Denmark Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Finland Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Norway Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Sweden Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Poland Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Russia Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Turkey Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Table APAC Oral Antidiabetic (OAD) Treatment Consumption by Country (2017-2022)

    • Figure China Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Thailand Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Singapore Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Philippines Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Table South America Oral Antidiabetic (OAD) Treatment Consumption by Country (2017-2022)

    • Figure Brazil Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Colombia Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Chile Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Argentina Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Peru Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Table GCC Oral Antidiabetic (OAD) Treatment Consumption by Country (2017-2022)

    • Figure Bahrain Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Oman Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Qatar Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Table Africa Oral Antidiabetic (OAD) Treatment Consumption by Country (2017-2022)

    • Figure Nigeria Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Africa Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Egypt Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Algeria Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Table Oceania Oral Antidiabetic (OAD) Treatment Consumption by Country (2017-2022)

    • Figure Australia Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Oral Antidiabetic (OAD) Treatment Consumption and Growth Rate (2017-2022)

    • Table Mannkind Company Details

    • Table Mannkind Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mannkind Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

    • Table Mannkind Oral Antidiabetic (OAD) Treatment Product Portfolio

    • Table Merck Company Details

    • Table Merck Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

    • Table Merck Oral Antidiabetic (OAD) Treatment Product Portfolio

    • Table Eli Lilly Company Details

    • Table Eli Lilly Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

    • Table Eli Lilly Oral Antidiabetic (OAD) Treatment Product Portfolio

    • Table Sanofi Company Details

    • Table Sanofi Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

    • Table Sanofi Oral Antidiabetic (OAD) Treatment Product Portfolio

    • Table Glenmark Company Details

    • Table Glenmark Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Glenmark Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

    • Table Glenmark Oral Antidiabetic (OAD) Treatment Product Portfolio

    • Table Boehringer Ingelheim Company Details

    • Table Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

    • Table Boehringer Ingelheim Oral Antidiabetic (OAD) Treatment Product Portfolio

    • Table Novartis Company Details

    • Table Novartis Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

    • Table Novartis Oral Antidiabetic (OAD) Treatment Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

    • Table Pfizer Oral Antidiabetic (OAD) Treatment Product Portfolio

    • Table AstraZeneca Company Details

    • Table AstraZeneca Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

    • Table AstraZeneca Oral Antidiabetic (OAD) Treatment Product Portfolio

    • Table Novo Nordisk Company Details

    • Table Novo Nordisk Oral Antidiabetic (OAD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novo Nordisk Oral Antidiabetic (OAD) Treatment Main Business and Markets Served

    • Table Novo Nordisk Oral Antidiabetic (OAD) Treatment Product Portfolio

    • Figure Global Sulphonylureas Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Biguanides Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Intestinal α-Glucosidase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Diabetics Treatment Centres Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oral Antidiabetic (OAD) Treatment Consumption Forecast by Country (2022-2028)

    • Table North America Oral Antidiabetic (OAD) Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Oral Antidiabetic (OAD) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Germany Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Oral Antidiabetic (OAD) Treatment Consumption Forecast by Country (2022-2028)

    • Figure China Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Oral Antidiabetic (OAD) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Brazil Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Oral Antidiabetic (OAD) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Oral Antidiabetic (OAD) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Oral Antidiabetic (OAD) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Australia Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Oral Antidiabetic (OAD) Treatment Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US